title: [Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases].
abstract: Serum concentrations of CA 19-9, CA 242, and CA 50 were determined in patients with hepatitis and liver cirrhosis without cholestasis. The study included 63 patients with chronic persistent hepatitis (group A), chronic active hepatitis (group B), and liver cirrhosis (group C). The control group (K) consisted of 82 patients with: peptic ulcer, colorectal polypi or diverticulosis of the colon. CA 19-9 level normal in the majority of patients with liver diseases, however, it was found to be increased in 4 (23%) of patients with liver cirrhosis. There was no statistically significant difference in the frequency of increased level of CA 19-9 between liver diseases and the control group. The rate of elevated serum level of CA 242 in patients with liver diseases and in control group was similar respectively 12%; 8.5%). The elevated CA 50 levels were most frequently found in patients with liver pathology (50% in liver cirrhosis and chronic active hepatitis; 36% in chronic persistent hepatitis).
  
  
  CONCLUSIONS
  The elevation of CA 50 serum level occurs very often in liver diseases, even when they are going without cholestasis. Thus, the antigen is not useful for differentiating between benign and cancer diseases of gastrointestinal tract. Antigen CA 50 is to be taken into account only after exclusion of the pathology of liver, especially cirrhosis. Other investigated antigens: CA 19-9 and CA 242 are influenced by liver diseases to a minor and neglectable extent. Antigen CA 19-9 is the marker of choice in gastrointestinal cancers.
authors.affiliation: III Katedry i Kliniki Chorób Wewnetrznych Slaskiej Akademii Medycznej w Katowicach.
authors.forename: J
authors.initials: J
authors.lastname: Nowak
authors.forename: D
authors.initials: D
authors.lastname: Jakubowska
authors.forename: A
authors.initials: A
authors.lastname: Wiczkowski
authors.forename: K
authors.initials: K
authors.lastname: Sprzaczkowska
authors.forename: T
authors.initials: T
authors.lastname: Stechły
authors.forename: W
authors.initials: W
authors.lastname: Zmudziński
authors.forename: P
authors.initials: P
authors.lastname: Grzesik
authors.forename: R
authors.initials: R
authors.lastname: Walas
authors.forename: B
authors.initials: B
authors.lastname: Jarzab
mesh_terms: D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood / Q000276:immunology*; D018395:CA-19-9 Antigen / Q000097:blood / Q000276:immunology*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D018395:CA-19-9 Antigen